Copyright © Inderes 2011 - present. All rights reserved.

Oriola

0.96 EUR

-0.83 %

7,754 following
Corporate customer

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.83 %
-10.82 %
-16.87 %
-16.29 %
-17.87 %
-15.25 %
-31.91 %
-53.37 %
-48.03 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
177.17M EUR
Turnover
121.04K EUR
P/E (adj.) (26e)
11.61
EV/EBIT (adj.) (26e)
1.33
P/B (26e)
1.7
EV/S (26e)
0.02
Dividend yield-% (26e)
4.18 %
Coverage
Recommendation
Accumulate
Target price
1.20 EUR
Updated
25.02.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 14.01.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.4
2026

Interim report Q1'26

17.7
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Awaiting news on strategy review - Evli

Oriola’s Q4 was overall rather good, with double-digit growth exceeding expectations while profitability in Wholesale remained soft. For now, all eyes are on news from the strategy review and Capital Markets Day in May.

Oriola
Third party research

Oriola: Growth pace remains solid - Evli

Oriola posted overall good figures in Q4. Net sales and invoicing growth was in the double-digits, and the pace exceeded our expectations. The adj. EBITDA of EUR 9.9m fell slightly short of our EUR 10.3m expectations, as the profitability in the Wholesale...

Oriola
Third party research

Oriola: Expecting a busy year ahead - Evli

We expect continued good growth in Q4 and fairly flat margin development q/q. 2026 is looking to be a busy year, but if one should be excited about the actions to be taken still remains to be seen.

Oriola
Forum discussions
NOT LIKE THIS! That was some tough reading, as the whole report was pure bullshit bingo. The dividend was halved, and Kronans is still a complete farce. The ERP project apparently takes forever and has failed completely; AI was also mentioned in the report, because well, I don’t ...
2/25/2026, 9:06 AM
by Trivial
17
Some companies have a tendency to constantly change their reporting, making it hard to keep up, and Oriola is one of them. Here comes one big and sensible change: Oriola’s revenue will in the future reflect the distribution fees they receive, not the price of medicines (which Oriola...
3/20/2026, 10:41 AM
by Rauli_Juva
15
Oriola’s communications may still be following the Inderes forum. I’ll post a few comments now that the financial statements have been reported. Significantly more information regarding the joint venture was published in connection with the financial statements, and in particular...
3/11/2026, 9:26 AM
by Aktivisti26
9
Iikka interviewed Oriola’s CEO Katarina Gabrielson regarding the Q4 results Inderes Oriola Q4'25: Double‑digit revenue growth - Inderes Aika: 25.02.2026 klo 14.26 Oriola’s revenue grew 14% in Q4. Oriola’s adjusted EBITDA improved to 9.9 MEUR from 9.4 MEUR in the comparison period...
2/25/2026, 3:02 PM
by Sijoittaja-alokas
7
Good points @aktivisti26 and I completely agree. What’s interesting in the valuation of that joint venture is that the growth and discount rate values are provided in the annual report, but the margin isn’t… of course Oriola has stated that Kronans aims for “profitability in line...
3/11/2026, 11:10 AM
by Rauli_Juva
6
Rauli has written extensively about Oriola’s balance sheet situation. Oriola’s balance sheet presents a contradictory situation, as the company is net debt-free, but its equity ratio is low. In addition, there is a clear risk of a write-down in the value of the joint venture, which...
3/10/2026, 5:43 AM
by Sijoittaja-alokas
6
Of course the ERP isn’t ready yet, as it was stated at the beginning of 2024 that the project would last until 2027. However, it was mentioned on the call that it hasn’t been decided yet whether the old system will be used first in the new distribution center to be built in Finland...
2/25/2026, 10:22 AM
by Rauli_Juva
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.